Middle East And Africa Colorectal Cancer Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 142.81 Million |
 Taille du marché (année de prévision) |
USD 242.45 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché du diagnostic du cancer colorectal au Moyen-Orient et en Afrique, par type de produit (instruments et consommables et accessoires), type de test (examen des selles, test sanguin, test d'imagerie, marqueurs tumoraux, biopsie et autres), stades du cancer (stade 0, stade I, stade II, stade III et stade IV), type de cancer (adénocarcinome, lymphome colorectal, tumeurs stromales gastro-intestinales, tumeurs carcinoïdes et autres), groupe d'âge (gériatrique, adultes et pédiatrique), utilisateur final (hôpitaux, centres de diagnostic, centres de recherche sur le cancer, centres de chirurgie ambulatoire, instituts universitaires et autres) Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché du diagnostic du cancer colorectal au Moyen-Orient et en Afrique
La sensibilisation croissante au cancer colorectal au Moyen-Orient et en Afrique a renforcé la demande du marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'augmentation des processus et techniques de diagnostic améliorés contribue également à la demande croissante de tests de diagnostic du cancer colorectal.
Le marché du diagnostic du cancer colorectal au Moyen-Orient et en Afrique devrait croître de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 6,9 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 242,45 millions USD d'ici 2030 contre 142,81 millions USD en 2022.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable pour 2020-2016) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par type de produit (instruments, consommables et accessoires), type de test (examen des selles, analyse sanguine, test d'imagerie, marqueurs tumoraux, biopsie et autres), stades du cancer (stade 0, stade I, stade II, stade III et stade IV), type de cancer (adénocarcinome, lymphome colorectal, tumeurs stromales gastro-intestinales, tumeurs carcinoïdes et autres), groupe d'âge (gériatrie, adultes et pédiatrie), utilisateur final (hôpitaux, centres de diagnostic, centres de recherche sur le cancer, centres de chirurgie ambulatoire, instituts universitaires et autres) |
|
Pays couverts |
Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël et reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Royal Philips NV, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Merck KGaA, FUJIFILM Corporation, Agilent Technologies, Inc., BD, General Electric Company, Siemens Healthcare GmbH, Abbott, Neusoft Corporation, BioFire Diagnostics, QIAGEN, Hologic, Inc., PlexBio, GE HealthCare.
|
Définition du marché du diagnostic du cancer colorectal au Moyen-Orient et en Afrique
Colorectal cancer starts in the colon or the rectum. Depending on where they start, these cancers can also be called colon cancer or rectal cancer. Colon cancer and rectal cancer are often grouped because they have many features in common. Colorectal cancer is a disease in which cells in the colon or rectum grow out of control. Sometimes it is called colon cancer, short. The colon is the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus.
Sometimes abnormal growths, called polyps, form in the colon or rectum. Over time, some polyps may turn into cancer. Screening tests can find polyps so they can be removed before becoming cancer. Screening also helps find colorectal cancer early, when treatment works best.
Middle East and Africa Colorectal Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
-
Growing prevalence of colorectal cancer
Colorectal cancer is sometimes called colon cancer, which is a term that combines colon cancer and rectal cancer, which begins in the rectum. Colon cancer typically affects older adults, though it can happen at any age. It usually begins as small, noncancerous (benign) clumps of cells called polyps forming inside the colon. Over time some of these polyps can become colon cancers.
In 2022, according to the American Cancer Society's (ACS) publication, the number of colorectal cancers in the United States for 2023 was 106,970 new cases of colon cancer, 46,050 new cases of rectal cancer, and overall, the lifetime risk of developing colorectal cancer is about 1 in 23 for men and 1 in 26 for women.
-
Rise in the number of patients suffering from diverticulitis and ulcerative colitis.
Diverticulitis refers to inflammation of the diverticula, which are small pouches that form in the colon lining. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) where people develop inflammation and ulcers in the lining of the large intestine. Treatment options include antibiotics, a temporary, clear liquid diet, pain relief medication, and surgery to remove part of the colon for a few cases only.
In June 2022, according to the information provided by National Center for Biotechnology Information (NCBI), Ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year. Its prevalence is 156 to 291 cases per 100,000 persons per year. Ulcerative colitis has a bimodal pattern of incidence. The main onset peaks between the age of 15 and 30 years. A second and smaller peak of incidence occurs between the age of 50 and 70 years.
Opportunity
-
Rise in healthcare expenditure for cancer diagnosis and treatment
Healthcare expenditure has increased worldwide as people's disposable income in various countries is increasing. Moreover, government bodies and healthcare organizations are taking the initiative by accelerating healthcare expenditure to meet population requirements. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities on colorectal cancer diagnostics as the disorder has been highly prevalent in recent years.
Also, the strategic initiatives key market players take will provide structural integrity and future opportunities for the colorectal cancer diagnostics market in the forecast period of 2023-2030.
Restraint/Challenge
- Increased cost, safety, and convenience issues
Colorectal cancer is fatal, and the diagnosis process of this type of cancer also has safety issues. It is also not cost-effective. One of the costliest medical disorders to treat Middle East and Africa is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and various systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.
Post COVID-19 Impact on Colorectal Cancer Diagnostics Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market.
Recent Developments
- In August 2022, Bio-Rad Laboratories Inc. completed its acquisition of Curiosity Diagnostics, a Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and Middle East and Africa presence in the market.
- In January 2022, QIAGEN announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems. This has helped the company to expand its product portfolio in the market and helped the company to increase its overall revenue.
Middle East and Africa Colorectal Cancer Diagnostics Market Scope
The Middle East and Africa colorectal cancer diagnostics market is segmented into product type, test type, cancer type, cancer stages, age group, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the Middle East and Africa colorectal cancer diagnostics market is segmented into instruments, consumables & accessories.
Test Type
- Imaging Test
- Stool Examination
- Tumor Markers
- Biopsy
- Blood Test
- Others
On the basis of test type, the Middle East and Africa colorectal cancer diagnostics market is segmented into stool examination, imaging test, biopsy, blood test, tumor markers, and others.
Cancer Type
- Adenocarcinoma
- Colorectal Lymphoma
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Others
On the basis of cancer type, the Middle East and Africa colorectal cancer diagnostics market is segmented into adenocarcinoma, colorectal lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others.
Cancer Stages
- Stage 0
- Stage i
- Stage ii
- Stage iii
- Stage iv
On the basis of cancer stages, the Middle East and Africa colorectal cancer diagnostics market is segmented into stage 0, stage I, stage II, stage III, and stage IV.
Age Group
- Geriatric
- Adults
- Pediatric
On the basis of age group, the Middle East and Africa colorectal cancer diagnostics market is segmented into geriatric, adults, and pediatric.
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Centers,
- Ambulatory Surgical Centers,
- Academic Institutes
- Others
On the basis of end users, the Middle East and Africa colorectal cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, academic institutes, and others.
Middle East and Africa Colorectal Cancer Diagnostics Market Regional Analysis/Insights
The colorectal cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, cancer stages, age group, and end user, as referenced above.
The countries covered in this market report are South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.
- In 2023, South Africa is dominating the Middle East and Africa colorectal cancer diagnostics market in terms of market share and revenue. It will continue to flourish its dominance during the forecast period. This is due to rising incidence and prevalence of colorectal nodules & cancer.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Colorectal Cancer Diagnostics Market Share Analysis
Le paysage concurrentiel du marché du diagnostic du cancer colorectal fournit des détails sur un concurrent. Les détails comprennent un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus ne concernent que les entreprises qui se concentrent sur le marché du diagnostic du cancer colorectal.
Certains des principaux acteurs opérant sur le marché du diagnostic du cancer colorectal au Moyen-Orient et en Afrique sont Koninklijke Philips NV, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Merck KGaA, FUJIFILM Corporation, Agilent Technologies, Inc., BD, General Electric Company, Siemens Healthcare GmbH, Abbott, Neusoft Corporation, BioFire Diagnostics, QIAGEN, Hologic, Inc., PlexBio, GE HealthCare.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS:
6 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS
6.1 REGULATORY SCENARIO IN THE U.S
6.2 REGULATORY SCENARIO IN AUSTRALIA
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS.
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATORY POLICIES
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS.
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 PATHOLOGY-BASED INSTRUMENTS
8.2.1.1 PCR INSTRUMENTS
8.2.1.2 SLIDE STAINING SYSTEMS
8.2.1.3 TISSUE PROCESSING SYSTEMS
8.2.1.4 CELL PROCESSORS
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.2.2 IMAGING INSTRUMENTS
8.2.2.1 ULTRASOUND SYSTEMS
8.2.2.2 CT SYSTEMS
8.2.2.3 MRI SYSTEMS
8.2.2.4 OTHERS
8.2.3 BIOPSY INSTRUMENTS
8.2.4 OTHERS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 DNA POLYMERASE KITS
8.3.1.3 NUCLEIC ACID ISOLATION KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 OTHER CONSUMABLES
9 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 STOOL EXAMINATION
9.3 BLOOD TEST
9.3.1 COMPLETE BLOOD COUNT (CBC)
9.3.2 TUMOR MARKER TEST
9.3.3 LIVER ENZYME BLOOD TEST
9.4 IMAGING TEST
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.4.2 MRI
9.4.3 ULTRASOUND
9.4.4 POSITION EMISSION TOMOGRAPHY (PET)
9.4.5 OTHERS
9.5 TUMOR MARKERS
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA)
9.5.2 CA19-9 BIOMARKER TEST
9.5.3 CA 50 MARKER TEST
9.5.4 OTHERS
9.6 BIOPSY
9.7 OTHERS
10 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES
10.1 OVERVIEW
10.2 STAGE III
10.3 STAGE IV
10.4 STAGE II
10.5 STAGE I
10.6 STAGE 0
11 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 GERIATRIC
11.3 ADULTS
11.4 PEDIATRIC
12 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
12.1 OVERVIEW
12.2 ADENOCARCINOMA
12.3 COLORECTAL LYMPHOMA
12.4 GASTROINTESTINAL STROMAL TUMORS
12.5 CARCINOID TUMORS
12.6 OTHERS
13 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 DIAGNOSTIC CENTERS
13.4 CANCER RESEARCH CENTERS
13.5 AMBULATORY SURGICAL CENTERS
13.6 ACADEMIC INSTITUTES
13.7 OTHERS
14 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SOUTH AFRICA
14.1.2 SAUDI ARABIA
14.1.3 U.A.E.
14.1.4 EGYPT
14.1.5 ISRAEL
14.1.6 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F. HOFFMANN- LA ROCHE LTD
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 KONINKLIJKE PHILIPS N.V.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 THERMO FISHER SCIENTIFIC INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 ILLUMINA, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 QUEST DIAGNOSTICS INCORPORATED
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 AGILENT TECHNOLOGIES, INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BEIJING O&D BIOTECH CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIOFIRE DIAGNOSTICS
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BIO-RAD LABORATORIES, INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 CANON MEDICAL SYSTEMS CORPORATION.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 FONAR CORP.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 FUJIFILM CORPORATION
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 GE HEALTHCARE.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 HOLOGIC, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 MEDONICA CO. LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 MERCK KGAA
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MYRIAD GENETICS, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 NEUSOFT CORPORATION
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENT
17.22 PLEXBIO
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 QIAGEN
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 SIEMENS HEALTHCARE GMBH
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 1.2.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENT
17.25 STERNMED GMBH
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
17.26 TIME MEDICAL HOLDING.
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA CONSUMABLES AND ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA STOOL EXAMINATION IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA BIOPSY IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA STAGE III IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA STAGE IV IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA STAGE II IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA STAGE I IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA STAGE 0 IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA GERIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA ADULTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA PEDIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA ADENOCARCINOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA COLORECTAL LYMPHOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA CARCINOID TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA HOSPITALS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA CANCER RESEARCH CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA ACADEMIC INSTITUTES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 SOUTH AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 SOUTH AFRICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 SOUTH AFRICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 SOUTH AFRICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 SOUTH AFRICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 SOUTH AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 SOUTH AFRICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 SOUTH AFRICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 SOUTH AFRICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 SOUTH AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 71 SOUTH AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 72 SOUTH AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 73 SOUTH AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 74 SAUDI ARABIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 SAUDI ARABIA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 SAUDI ARABIA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 SAUDI ARABIA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 SAUDI ARABIA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 SAUDI ARABIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 SAUDI ARABIA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 SAUDI ARABIA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 SAUDI ARABIA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 SAUDI ARABIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 86 SAUDI ARABIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 87 SAUDI ARABIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 88 SAUDI ARABIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 U.A.E. COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 U.A.E. INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 U.A.E. PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 U.A.E. IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 U.A.E. CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 U.A.E. KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.A.E. REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 U.A.E. COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 97 U.A.E. BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 U.A.E. IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 U.A.E. TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 U.A.E. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 101 U.A.E. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 102 U.A.E. COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 103 U.A.E. COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 104 EGYPT COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 105 EGYPT INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 EGYPT PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 EGYPT IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 EGYPT CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 EGYPT KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 110 EGYPT REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 111 EGYPT COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 EGYPT BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 EGYPT IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 EGYPT TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 115 EGYPT COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 116 EGYPT COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 117 EGYPT COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 118 EGYPT COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 119 ISRAEL COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 ISRAEL INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 ISRAEL PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 ISRAEL IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 ISRAEL CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 124 ISRAEL KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 ISRAEL REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 126 ISRAEL COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 ISRAEL BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 ISRAEL IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 ISRAEL TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 ISRAEL COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 131 ISRAEL COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 132 ISRAEL COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 133 ISRAEL COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 134 REST OF MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT COLORECTAL CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET
FIGURE 14 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 19 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022
FIGURE 23 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 27 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 31 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 34 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 35 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 39 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 40 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 MIDDLE EAST AND AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
